EKF Diagnostics (LON:EKF) Insider Julian Baines Acquires 85,000 Shares

EKF Diagnostics Holdings plc (LON:EKF) insider Julian Baines purchased 85,000 shares of the company’s stock in a transaction dated Monday, December 15th. The shares were purchased at an average cost of GBX 23 per share, for a total transaction of £19,550.

EKF Diagnostics Stock Performance

EKF stock opened at GBX 24.90 on Wednesday. EKF Diagnostics Holdings plc has a 1-year low of GBX 18.40 and a 1-year high of GBX 32. The business has a 50-day moving average price of GBX 25.78 and a 200 day moving average price of GBX 27.29. The company has a market capitalization of £108.41 million, a P/E ratio of 18.44 and a beta of 0.57. The company has a debt-to-equity ratio of 0.34, a current ratio of 4.60 and a quick ratio of 1.77.

EKF Diagnostics (LON:EKF) last issued its earnings results on Tuesday, September 16th. The company reported GBX 0.43 earnings per share (EPS) for the quarter. EKF Diagnostics had a net margin of 9.37% and a return on equity of 7.03%. As a group, equities research analysts forecast that EKF Diagnostics Holdings plc will post 2.2987842 EPS for the current fiscal year.

About EKF Diagnostics

EKF is an AIM-listed global diagnostics business focussed on:

● Point-of-Care analysers in the key areas of Hematology and Diabetes

● Life Sciences services provide specialist manufacture of enzymes and custom products for use in diagnostic, food and industrial applications.

EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.